ABEO Stock — Abeona Therapeutics Inc.

Up next

Next earnings call

Mar 16, 2027 Est · unconfirmed · in 17 wks

Q1 2026 earnings call transcript

call held May 13, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 11

Investor event

ZivaSkin reaches 15 patients as ABO801 advances

Abeona Therapeutics said ZivaSkin treated 15 patients across eight activated QTCs, four of which have treated patients. Newly acquired ABO801 has two phase three studies, with another planned under a $50 to $60 million, two-and-a-half-year development budget.

6 source passages

For those new to the story of Abiona, we are a commercial stage rare disease company. We launched ZivaSkin, which was FDA approved in 2025. We've treated six patients in the third quarter. Also, that sums up to 15 patients since launch last year. Now we have eight QTCs activated across the U.S., of which four have treated their patients. our new chapter that we announced yesterday with the acquisition of ABO801, which was previously called as APT-1011. It's not just a late stage phase three ready asset. It has a robust established clinical foundation with the data that has been generated through two phase three studies. the $50 to $60 million over the two-and-a-half-year timeline Open the document at this passage

Nov 9

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Abeona acquires Phase 3-ready ABO-801 for eosinophilic esophagitis

Abeona acquired Phase 3-ready ABO-801 for eosinophilic esophagitis from Ellodi for $20 million in stock. Ellodi is eligible for $30 million upon FDA approval and up to an additional $30 million upon sales milestones.

Revenue $13.49M Net loss $4.81M Diluted EPS -$0.08

Read from the MD&A section

4 source passages

On November 9, 2026 (“the Closing Date”), we announced the acquisition of APT-1011, now ABO-801, from Ellodi Pharmaceuticals L.P. (“Ellodi”). ABO-801 is a Phase 3-ready, once-daily oral disintegrating tablet formulation of fluticasone propionate in development for eosinophilic esophagitis (EoE). Under the terms of the asset purchase agreement, we issued Ellodi $20 million in value of our common stock, par value $0.01 per share, which amounted to 4,494,383 shares (the “Upfront Shares”), based on the 20-trading-day volume weighted average price of the our common stock ending on the trading day immediately before the Closing Date. Ellodi is also eligible to receive payments of $30 million upon FDA approval of ABO-801 and up to an additional $30 million upon achievement of specified sales milestones. Open the document at this passage

Nov 9

Current report 8-K

ZEVASKYN revenue rises 18% as quarterly loss narrows

Abeona Therapeutics Inc. reported third-quarter ZEVASKYN revenue of $13.5 million, up 18%, a net loss of $(4.8) million and $134.9 million in cash, cash equivalents and short-term investments. It also acquired ABO-801 and announced $30 million in PIPE financing.

Financial results, Regulation FD disclosure

5 source passages

Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported third-quarter 2026 financial results and provided an update on the commercial launch of ZEVASKYN. Net ZEVASKYN revenue for the quarter ended September 30, 2026 was $13.5 million, an 18% increase compared with $11.4 million for the second quarter of 2026. Net loss was $(4.8) million, or $(0.08) per basic and diluted common share, for the quarter ended September 30, 2026, compared with a net loss of $(20.2) million, or $(0.35) per basic and diluted common share, for the second quarter of 2026. Cash, cash equivalents and short-term investments totaled $134.9 million as of September 30, 2026, compared with $146.8 million as of June 30, 2026. Abeona acquired APT-1011, now ABO-801, from Ellodi Pharmaceuticals and announced a $30 million PIPE financing. Open the document at this passage

Nov 9

Current report 8-K Events of Nov 6

APT-1011 acquisition and approximately $30 million private placement

Abeona Therapeutics Inc. acquired APT-1011 assets from Ellodi Pharmaceuticals, L.P. for $20 million in stock, with $30 million due upon FDA approval and up to $30 million in sales milestones. It also arranged an approximately $30 million private placement.

Entered into a material agreement, Completed an acquisition or sale of assets, Unregistered sale of equity, Regulation FD disclosure Read from the first part of this long document

4 source passages

On November 6, 2026 (the “Closing Date”), Abeona Therapeutics Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Ellodi Pharmaceuticals, L.P., a Delaware limited partnership (“Ellodi”), pursuant to which Ellodi sold and assigned to the Company, and the Company purchased and assumed from Ellodi, substantially all assets related to the research, development, manufacture, and commercialization of Ellodi’s clinical-stage development candidate known as APT-1011 (the “Transaction”). Pursuant to the Asset Purchase Agreement, the Company issued to Ellodi $20 million in value of Company common stock, par value $0.01 per share (the “Common Stock”), which amounted to 4,494,383 shares (the “Upfront Shares”), based on the 20-trading-day volume weighted average price of the Company’s Common Stock ending on the trading day immediately before the Closing Date. In addition, the Company is obligated to pay Ellodi (i) payments of $30 million upon FDA approval of a New Drug Application for APT-1011 and up to $30 million upon the achievement of certain sales milestones, and (ii) certain royalty payments based on the net sales of APT-1011 with royalty percentage tiers ranging from low to mid teen percentages. On November 6, 2026, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a group of investors (the “Purchasers”) providing for the private placement (the “Private Placement”) to the Purchasers of (i) 6,400,000 shares of Common Stock (the “Private Placement Shares”), and (ii) pre-funded warrants to purchase 1,600,043 shares of Common Stock (the “Pre-Funded Warrants”, and together with the Private Placement Shares, the “Private Placement Securities”), for an aggregate purchase price of approximately $30 million. Open the document at this passage

Sep 16

Investor event

Morgan Stanley 24th Annual Global Healthcare Conference AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$39.01M

Trailing 12 months

Net income (TTM)

−$62.53M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

-1,536.9%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-48.0%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$123.10M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+6.7%

Year over year · more shares

Price change (1Y)

-46.6%

Trailing year

Short interest

29.5%

Latest settlement · 21.7 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

· $7.00M −$7.24M '20 Q3 · $346,000 −$22.04M '22 Q1 · $1.00M −$4.10M '22 Q2 ▲250% $3.50M −$16.65M '23 Q2 · $400,000 $108.83M '25 Q2 · $8.72M −$17.07M '26 Q1 ▲2745% $11.38M −$20.19M '26 Q2 LATEST · $13.49M −$4.81M '26 Q3

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −55%

below

Price vs 50-day avg −48%

below

RSI (14) 21

oversold

MACD trend Negative

52-week position 3%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −45%

trailing

6-month return −56%

trailing

YTD return −54%

this year

Relative strength −56%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Distributing

90 of 127 funds reported for Sep 30 · net -1.7M sh shares · +6 new

Insider flow Distributing

Net -$296.4K over 90 days · 100% sells

Short interest Falling

29.54% of shares out · ▼ -1.9% MoM · 21.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Squeeze score 66

elevated · 0–100

Fundamentals

Strong

Revenue growth +258%

Y/Y

EPS growth +165%

Y/Y

Free cash flow $-84.3M

Balance sheet $58.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 64%

annualized · 1-yr

Max drawdown −69%

past year

ATR 13.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−55% Bearish

Price vs 50-day avg

−48% Bearish

RSI (14)

21 Neutral

MACD trend

Negative Bearish

52-week position

3% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Distributing

90 of 127 funds reported for Sep 30 · net -1.7M sh shares · +6 new

Insider flow Distributing

Net -$296.4K over 90 days · 100% sells

Short interest Falling

29.54% of shares out · ▼ -1.9% MoM · 21.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $2 · 3% Range high $7

vs 200-day avg -55% vs 50-day avg -48%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
patient treatments completed since launch	12	since launch through Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ABEO Abeona Therapeutics Inc. this stock	$138.30M	-54.1%	+258.2%	—	29.5%
VRTX Vertex Pharmaceuticals Inc	$136.56B	+18.8%	+46.2%	34.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$98.84B	+23.8%	+20.8%	21.1	2.1%
MRNA Moderna, Inc.	$90.38B	+657.4%	+4.3%	—	8.2%
CSLLY Csl Ltd	$66.05B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

118

% held: 65.9%
Reported: 90 of 127
Top holder: Nantahala Capital Managem…

Held Float

View

Held by Funds

Fund positions

96

View

Short & Settlement

Short Interest Falling

Shares short

16.9M

Days to cover: 21.7d
Change: -335.0K sh

View

Short Volume

Short vol %

25%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

1

Value: $5
As of: Oct 13, 2026

View

Off-Exchange

Off-exchange %

47.5%

Week of: Oct 5, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$296.4K

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Financials

Revenue (FY)

$5.8M

Net income (FY): $71.2M
EPS diluted: $1.01

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Nov 11, 2026
This year: 24

Abeona Therapeutics said ZivaSkin treated 15 patients across eight activated QTCs, four of which have treated patients. Newly acquired ABO801 has two phase three studies, with another planned under a $50 to $60 million, two-and-a-half-year development budget.

View

Proposed Sales

Value

$47.4K

Shares: 9.2K
Filed: Sep 29, 2026

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 18, 2026

Last webcast: Nov 11, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
ABEO	-42.0%	-45.4%	-55.9%	-44.4%	-54.1%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	-44.6%	-44.2%	-56.4%	-44.2%	-64.7%

ABEO · Abeona Therapeutics Inc.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance